Sab Biotherapeutics Stock Today
| SABSW Stock | USD 0.11 0.04 26.67% |
Performance14 of 100
| Odds Of DistressOver 68
|
SAB Biotherapeutics is selling for under 0.11 as of the 17th of January 2025; that is 26.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0851. SAB Biotherapeutics has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 17th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of February 2021 | Category Healthcare | Classification Health Care |
SAB Biotherapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. More on SAB Biotherapeutics
Moving against SAB Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
SAB Stock Highlights
| Executive Chairman | Samuel Reich | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SAB Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand SAB Biotherapeutics' financial leverage. It provides some insight into what part of SAB Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SAB Biotherapeutics (SABSW) is traded on NASDAQ Exchange in USA. It is located in 777 W 41st St., Miami Beach, FL, United States, 33140 and employs 57 people. SAB Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
SAB Biotherapeutics generates negative cash flow from operations
Check SAB Biotherapeutics Probability Of Bankruptcy
SAB Biotherapeutics Historical Income Statement
SAB Stock Against Markets
SAB Biotherapeutics Corporate Executives
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward DVM | CoFounder Observer | Profile | |
| Michael King | EVP CFO | Profile | |
| Christoph MBA | Executive COO | Profile |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.